|
1. For treatment of moderate to severe vasomotor symptoms and/ or moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. PREMPRO 0.3 mg/ 1.5 mg PREMPRO 0.45 mg/ 1.5 mg PREMPRO 0.625 mg/ 2.5 mg PREMPRO 0.625 mg/ 5 mg
PREMPHASE
Patients should be treated with the lowest effective dose. Generally women should be started at 0.3 mg/ 1.5 mg PREMPRO daily. Subsequent dosage adjustment may be made based upon the individual patient response. In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration should be given to changing the dose level. This dose should be periodically reassessed by the healthcare provider. Text Continues Below
2. For prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should be considered only for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. PREMPRO 0.3 mg/ 1.5 mg PREMPRO 0.45 mg/ 1.5 mg PREMPRO 0.625 mg/ 2.5 mg PREMPRO 0.625 mg/ 5 mg
PREMPHASE Patients should be treated with the lowest effective dose. Generally women should be started at 0.3 mg/ 1.5 mg PREMPRO daily. Dosage may be adjusted depending on individual clinical and bone mineral density responses. This dose should be periodically reassessed by the healthcare
provider. In patients where bleeding or spotting remains a problem, after appropriate evaluation, consideration should be given to changing the dose level. This dose should be periodically reassessed by the healthcare provider. PREMPHASE therapy consists of two separate tablets; one maroon 0.625 mg Premarin tablet taken daily on days 1 through 14 and one light-blue tablet, containing 0.625 mg conjugated estrogens and 5 mg of medroxyprogesterone acetate, taken on days 15 through 28. Page: << Prev | 1 | 2 | 3 | Next >>
|
.gif)
